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The insulin-like growth factors, IGF-I and IGF-II, have effects on metabolism, growth, proliferation and differentiation in many tissues and cell types (Jones and Clemmons, 1995) and are therefore important modulators of many aspects of physiology. Insulin-like growth factor actions are largely mediated via the type 1 IGF receptor (for review, see Werner et al., 1991) , although both peptides, particularly IGF-II, can bind to the type 2 IGF receptor. The role of the type 2 IGF receptor, especially with regard to the IGF system, is ill-defined but the receptor may be involved in IGF clearance. Access of ligands to these receptors is controlled by a family of six highly specific IGF-binding proteins (IGFBPs-1-6; Jones and Clemmons, 1995) , although it is now recognized that there are at least a further four molecules, so-called IGFBP-related proteins, which are similar to IGFBPs-1-6 but have a low affinity for IGF (Baxter et al., 1998) . The role of IGFBP-related peptides in controlling IGF action is, as yet, unknown whereas the traditional IGFBPs were originally regarded solely as IGF inhibitors, since their affinity for IGFs is substantially higher than that of the receptors. More recently, it has become apparent that modifications to the IGFBPs, for example proteolyis, phosphorylation or association with extracellular matrix, can influence IGFBP affinity for IGF and, therefore, IGF bioavailability and function.
Insulin-like growth factors during pregnancy
Insulin-like growth factors have a wider anatomical and developmental range of tissue expression than other peptide growth factors, indicating a key role for IGF-I and IGF-II in embryonic and fetal growth. This contention is evidenced in studies by Efstradiatis and co-workers that used mice in which null mutations were created by homologous recombination in the genes encoding IGF-I, IGF-II and the type 1 IGF receptor (Table 1 ; DeChiara et al., 1990; Baker et al., 1993; Liu et al., 1993) . Ablation of either the IGF-I or IGF-II gene resulted in embryonic and neonatal mice 40% smaller than their normal littermates. The IGF-II-deficient mice also had reduced placental growth but survived normally, whereas the mice lacking IGF-I showed increased neonatal death. Pup size was even smaller if both IGFs (30% of normal) or the type 1 IGF receptor (45% of normal) were removed, and these mice also died soon after birth. Mice carrying null mutations for both the receptor and IGF-I were identical to those lacking receptor only, whereas mice deficient in IGF-II as well as the type 1 IGF receptor were affected more severely and resembled those lacking both IGF-I and IGF-II.
In humans too, the IGF axis is disrupted in disorders of fetal growth; IGF-I concentrations are low in cord sera from intrauterine growth-restricted (IUGR) or small for gestational age (SGA) fetuses (Giudice et al., 1995) and are high in large for gestational age newborns (LGA; Giudice et al., 1995) .
Given the fundamental importance of the IGFs, it is also important to understand how their actions are regulated and, thus, there has been much interest in the role of the IGFBPs during pregnancy.
IGFBP-1 in pregnancy
In human pregnancy, IGFBP-1 is probably the most important member of the family of IGFBPs: it is the main secretory product of decidualized endometrial cells (Koistinen et al., 1986; Bell et al., 1988) , the predominant IGFBP in amniotic fluid (Drop et al., 1984) , a major IGF-binding species in fetal plasma (Drop et al., 1984) and its concentrations are increased in the maternal circulation during pregnancy.
IGFBP-1 in maternal circulation
Concentrations of IGFBP-1 in the circulation of pregnant women are at least double those in plasma from non-pregnant subjects (Westwood et al., 1994) . Concentrations increase steadily throughout the first trimester, peak around mid-gestation and Insulin-like growth factors and their binding proteins are key regulators of fetal and maternal tissue growth and development during human pregnancy. Insulin-like growth factors, particularly IGF-II, are produced in abundance by the trophoblast cells of the placenta, whereas one of the insulin-like growth factor binding proteins, IGFBP-1, is the major secretory product of the maternal decidualized endometrium. This spatial (and temporal expression) of the insulin-like growth factor axis infers a sophisticated paracrine regulatory mechanism for controlling insulin-like growth factor function. This paper reviews the potential roles of IGFBP-1 in human pregnancy by examining its effects on growth, metabolism and migration at the maternal-fetal interface and how these might be influenced by autocrine-paracrine post-translational modifications.
then remain fairly constant until delivery, decreasing markedly after birth (Wang et al., 1991; Gibson et al., 1999) . IGFBP-1 concentrations are higher in the maternal circulation of twin or multi-fetal pregnancies (Abbas et al., 1995) .
At term, maternal (Howell et al., 1985) and fetal (Verhaeghe et al., 1993; Giudice et al., 1995) IGFBP-1 concentrations correlate negatively with birth weight and, in pregnancies complicated by intrauterine growth retardation or pre-eclampsia, increased maternal and fetal IGFBP-1 concentrations have been observed (Giudice et al., 1997) .
IGFBP-1 phosphorylation
IGFBP-1 can be post-translationally phosphorylated on serine residues 101, 119 and 169 (Jones et al., 1993a) . The intracellular enzymes involved are unkown, although casein kinase I and II and cAMP-dependent protein kinase have been shown to phosphorylate IGFBP-1 in vitro (Frost and Tseng, 1991; Ankrapp et al., 1996) .
In the normal adult circulation, IGFBP-1 occurs as a single highly phosphorylated species (p-IGFBP-1; Westwood et al., 1994) and, therefore, it is likely that this is the only isoform the liver can produce . However, during pregnancy, the phosphorylation state of IGFBP-1 changes (Fig. 1) ; non-phosphorylated and three less phosphorylated variants are present in the maternal circulation (Westwood et al., 1994) . The concentrations of these isoforms increases from < 2 µg l -1 in non-pregnant subjects to 80 µg l -1 by the third trimester, although in most pregnancies (see below), there is also a proportionate increase in the concentration of the highly phosphorylated isoform (Westwood et al., 1994) .
IGFBP-1 in amniotic fluid
IGFBP-1 concentrations in amniotic fluid are three orders of magnitude greater than those measured in maternal serum (mg l -1 versus µg l -1 ; Westwood et al., 1994) . Thus, many studies of IGFBP-1 function in vitro have used IGFBP-1 purified from amniotic fluid. This IGFBP-1 is in the non-and less phosphorylated state since the highly phosphorylated species is not found in amniotic fluid (Jones et al., 1991; Westwood et al., 1994) . Several studies implicate maternal decidua as the likely source of this IGFBP-1. In addition to the highly phosphorylated species, decidualized endometrium secretes IGFBP-1 (see below) in the non-and less phosphorylated isoforms (Frost and Tseng, 1991; Martina et al., 1997; Westwood et al., 1998) . Furthermore, concentrations of IGFBP-1 in the amniotic fluid are low until the amnion fuses with the chorion-decidua at the beginning of the second trimester (Wathen et al., 1993) . It follows that the additional IGFBP-1 isoforms observed in the maternal circulation during pregnancy may originate at the fetal-maternal interface. In support of this hypothesis is the finding that, in nonpregnant women whose circulating IGFBP-1 concentrations are increased in response to oral oestrogen administration, non-and less phosphorylated isoforms cannot be detected; only the highly phosphorylated isoform is present .
Significance of IGFBP-1 phosphorylation
Phosphorylated IGFBP-1, especially the highly phosphorylated isoform usually present in adults, has a higher affinity for IGF-I than the non-and less phosphorylated isoforms (Jones et al., 1991; Westwood et al., 1997a) and this phenomenon is thought to explain the conflicting data surrounding IGFBP-1 biological activity. Studies reporting that IGFBP-1 has an inhibitory effect on IGF actions have used IGFBP-1 preparations containing predominantly phosphorylated isoforms, whereas potentiation of IGF activity has been observed only with the non-phosphorylated, low IGF-affinity isoform (Jones et al., 1991) . Phosphorylated IGFBP-1 has a substantially higher affinity for IGF-I than does the type 1 IGF receptor; thus, IGF-I will bind to the binding protein in preference to the receptor, resulting in inhibition of IGF activity. However, nonphosphorylated IGFBP-1 has an affinity for IGF-I similar to that of the receptor. It is possible that the receptor-ligand would be potentiated if the local concentration of IGF were increased by retaining IGF-IGFBP complexes at the cell surface. Conceivably, IGFBP-1 could act via this mechanism since it contains an Arg-Gly-Asp sequence that is recognized by integrin α 5 β 1 at the cell surface (Jones et al., 1993b) . Therefore, pregnancy-associated changes in IGFBP-1 phosphorylation status may regulate IGF-I bioavailability, with consequences for metabolism and growth in both fetal and maternal tissues.
Insulin-like growth factor system at the maternal-fetal interface
Insulin-like growth factors Han et al. (1996) have reported that both IGF-I and IGF-II mRNA are absent from human maternal decidualized endometrium, although both peptides, especially IGF-II, are present et al., 1993 in placental chorionic villi (cytotrophoblasts, mesodermal core and endothelium) and fetal membranes (amnion and chorion laeve) from as early as 6 weeks of pregnancy (Table 2) . IGF-II expression was most abundant in the trophoblastic columns of the anchoring villi, particularly in those cells at the leading edge of the column, indicating that IGF-II may have a role in trophoblast invasion of the maternal endometrium.
IGFBP-1
In humans, placental IGFBP expression is low and IGFBP-1 is not synthesized at all (Table 2 ; Han et al., 1996) . Nonetheless, IGFBP-1 protein is associated with syncytiotrophoblast and intermediate trophoblast of the fetal villi and chorion (Hill et al., 1993) and it is also present at the decidual-fetal interface (Hustin et al., 1994) .
However, all six IGFBPs are produced by human decidualized endometrium, and IGFBP-1 is the most abundant (Table 2; Hill et al., 1993; Han et al., 1996) . IGFBP-1 expression by endometrial glandular epithelial and stromal cells begins during the mid-secretory phase of the menstrual cycle, becoming increasingly abundant in the stroma during the late secretory phase, which is perhaps the cause of the increased IGFBP-1 concentrations in the circulation . IGFBP-1 concentrations increase further in the decidualized stroma of pregnancy (Zhou et al., 1994; Han et al., 1996) . In other species too, IGFBP-1 appears to have an important role in implantation and pregnancy; for example, rats (Croze et al., 1991) , cats (Boomsma et al., 1994) , monkeys (Coulter and Han, 1996) and baboons (Fazleabas et al., 1997) all demonstrate decidual expression of IGFBP-1, although cellular and temporal expression is not necessarily the same. However, in species that develop a placenta without a decidualized endometrium (for example, sheep), IGFBP-3 appears to be the important IGFBP for regulating IGF bioavailability in the uterine microenvironment (Peterson et al., 1998) .
Regulation of IGFBP-1 production at the maternal-fetal interface
Progesterone is a major regulator of IGFBP-1 production by the human endometrium. Using immunocytochemistry, Pekonen et al. (1992) found increased endometrial IGFBP-1 production in response to an intrauterine progestin implant, and IGFBP-1 concentrations were increased in medium conditioned by decidual explants or by endometrial stromal cells decidualized in vitro, in response to progesterone (Bell et al., 1991) .
Since it is likely that action of IGFs at the fetal-maternal interface are under paracrine-autocrine control, it is conceivable that they, in turn, will affect decidual IGFBP-1 production. Indeed, both IGF peptides regulate IGFBP-1 production by first trimester decidua in a biphasic manner; low concentrations stimulate IGFBP-1 production whereas high concentrations are inhibitory (Irwin et al., 1993; Westwood et al., 1997b) . As a result of this work, Guidice et al. (1994) proposed that the biphasic regulation of IGFBP-1 serves as an autocrine mechanism for regulating IGF activity on endometrial cellular mitosis in the local environment (see below). However, Thrailkill et al. (1990) reported only an inhibitory effect of IGF on decidual cells at term. Insulin is also an inhibitor of decidual IGFBP-1 production (Thrailkill et al., 1990) , whereas relaxin, which is structurally similar to the IGFs, positively regulates IGFBP-1 production (Bell et al., 1991) . There is also some evidence that IGFBP-1 output is influenced by non-hormonal factors; Liu et al., (1995) reported that human endometrial stromal cells, decidualized in vitro, were stimulated to produce IGFBP-1 by the presence of mouse embryos.
Post-translational modification of IGFBP-1 at the maternal-fetal interface
In addition to altering IGFBP-1 concentrations at the maternalfetal interface, effects of IGFBP-1 on IGF activity may be regulated by changes in its phosphorylation status. First trimester decidual cells, preferentially produce non-phosphorylated IGFBP-1 when incubated with IGF-II, which is a major product of the fetal trophoblast (Westwood et al., 1998) . IGF-I, insulin and medroxyprogesterone acetate do not have this effect. Furthermore, placental alkaline phosphatase at the trophoblast cell surface can dephosphorylate highly phosphorylated and less phosphorylated IGFBP-1 to produce the non-phosphorylated isoform that has a lower affinity for IGF-I (Westwood et al., 1998) . The mechanism by which IGF-II increases production of non-phosphorylated IGFBP-1 by first trimester decidual cells has not been investigated but may include altered intracellular kinase pathways or increased extracellular dephosphorylation of the phosphorylated isoforms. As a result of these studies, a paracrine model is proposed in which trophoblast-directed modulation of IGFBP-1 phosphorylation by decidual cells leads to enhanced IGF bioavailability (Fig. 2) .
Role of IGFBP-1 during human pregnancy
The role of IGFBP-1 during pregnancy is best described as controversial. Both stimulatory and inhibitory effects on IGF-mediated growth, metabolism and migration have been described, although, in general, the phosphorylation state of the IGFBP-1 preparation used has not been analysed.
Effects at the fetal-maternal interface
Migration. Successful implantation, placental development and consequent fetal growth depend upon adequate migration of IGF-II-producing trophoblasts into a maternal decidual environment rich in IGFBP-1. The ability of IGFBP-1 to influence cell migration was recognized originally by Jones et al. (1993b) . Using Chinese hamster ovary cells, Jones and co-workers demonstrated a stimulatory effect of IGFBP-1 that depends upon the interaction of its RGD site with integrin α 5 β 1 (Jones et al., 1993b) . The migration of cells transfected with mutant (tryptophan for arginine substitution in the RGD sequence) IGFBP-1 was attenuated by 80% when compared with cells expressing the native protein. Addition of the wild-type protein to the media of these cells restored their ability to migrate and this response was blocked by the simultaneous addition of a synthetic RGD-containing peptide. Regardless of IGFBP-1 RGD status (mutant or wild type), IGF-I did not alter the migration rate, indicating that the effect of IGFBP-1 is direct.
IGFBP-1 also stimulates human trophoblast cell migration both in a monolayer wounding assay and a trans-Matrigel barrier migration assay (Irving and Lala, 1995; Hamilton et al., 1998) . IGFBP-1 was found to augment the effect of IGF-II as well as having autonomous effects. The effect of IGFBP-1 was abrogated by an antibody to integrin α 5 , although the invasive response to IGF-II was unaffected by an anti-type 1 IGF receptor antibody, leading to speculation that IGF-II may mediate its invasive actions via the type 2 IGF receptor. Indeed, the type 2 IGF receptor has been shown to mediate IGF-II-induced migration in several cell lines (Minniti et al., 1992; Volpert et al., 1996) .
Conflicting data on the role of IGFBP-1 in regulating trophoblast invasion has come from the laboratories of Guidice and co-workers. This group has tendered a model of human implantation in which migration of trophoblasts is impeded by the paracrine production of IGFBP-1 by the decidualized Zhou et al., 1994; Han et al., 1996 Trophoblast + +++ - Hill et al., 1993; Hustin et al., 1994; Zhou et al., 1994; Han et al.,1996 The number of +s represent the abundance of a peptide, with ++++ representing the most abundance and + representing present but not particularly abundant.
endometrium. They propose that the high concentrations of IGFBP-1 will interact via its RGD sequence with the α 5 β 1 integrin expressed on the cell membrane of the invading trophoblasts. Furthermore, they suggest that concentrations of this maternal 'restraint' are controlled by locally produced IGF-II (Guidice et al., 1994) . Support for this hypothesis comes from a co-culture model of second trimester human cytotrophoblast and human endometrial stromal cells decidualized in vitro (Irwin and Giudice, 1998) . In this system, cytotrophoblasts plated onto decidual multilayers did not penetrate the stromal cells unless decidual IGFBP-1 production was switched off by including insulin in the cultures during the decidualization phase. Under these conditions, 79% of the trophoblasts had invaded the stromal multilayers after 18 days of co-culture. The insulin-treated co-cultures were incubated with exogenous IGFBP-1 or IGFBP-3 (a structurally similar protein that does not have an RGD sequence) to refute the possibility that insulin stimulates trophoblast migration directly. In the presence of IGFBP-1, the cytotrophoblasts remained on the surface and did not penetrate the decidual multilayer. However, exogenous IGFBP-3 did not prevent invasion.
The studies described above demonstrate that IGFBP-1 affects trophoblast migration, although whether its role is to enhance or restrict trophoblast migration and, thus, placental development remains uncertain at present. Irwin and Giudice (1998) used a more physiological model, although trophoblasts isolated from second trimester are recognized to have reduced invasive potential compared with first trimester cells. Their study also used supraphysiological doses of IGFBP-1, which may have blocked endogenous IGF activity. The studies of Irving and Lala (1995), Hamilton et al., (1998) and Irwin and Guidice (1998) did not consider the effect of phosphorylation on the ability of IGFBP-1 to modulate cytotrophoblast migration, despite the early work of Jones et al. (1993b) indicating that, in addition to an intact RGD sequence, another region of IGFBP-1 is required to initiate intracellular signalling upon binding to α 5 β 1 integrin. Bischof et al. (1998) suggested that IGFBP-1 affects trophoblast migration by influencing gelatinolytic and, hence, extracellular matrix-degrading activities.
Proliferation. There is relatively little data relating to the effects of the IGFs on cellular proliferation at the fetal-maternal interface. IGFBP-1 has inhibitory effects on IGF binding and IGF-mediated mitogenesis in a choriocarcinoma cell line (Ritvos et al., 1988) , although Hamilton et al. (1998) found proliferation of extravillous trophoblast in primary cultures to be unaffected by IGF-I, IGF-II or IGFBP-1. In non-decidualized stromal cells, IGF-I-stimulated DNA synthesis was inhibited by IGFBP-1, irrespective of phosphorylation status (Frost et al., 1993) , whereas in cells decidualized in vitro, IGF-induced mitogenesis was inversely correlated with endogenous IGFBP-1 concentrations. Low concentrations of IGFBP-1 are thought to localize IGFs to the cell surface, thereby promoting its interaction with the type 1 IGF receptor, which, in turn, inhibits further IGFBP-1 production and, therefore, stimulates endometrial cellular mitosis (Irwin et al., 1993; Guidice et al., 1994) . Proposed mechanisms by which insulin-like growth factor binding protein 1 (IGFBP-1) could potentiate insulin-like growth factor (IGF) action. IGF-II produced by trophoblasts stimulates decidualized endometrium to produce preferentially non-phosphorylated IGFBP-1 and the presence of placental alkaline phosphatase ensures the predominance of this isoform. Non-phosphorylated IGFBP-1 has a lower affinity for IGF-I, hence, bioavailability for IGF-I is increased. Non-phosphorylated IGFBP-1 is also susceptible to proteolysis, resulting in fragments that bind neither IGF peptide; by this mechanism, IGF-II bioavailability could be increased also. It is likely that the ability differentially to modulate IGF-I and IGF-II bioavailability by post-translational modification of IGFBP-1 may provide a sophisticated mechanism for controlling IGF-I (for example, metabolism) versus IGF-II (for example, migration) actions at the fetal-maternal interface.
the placenta. Thus, IGFBP-1 may influence fetal growth by affecting IGF-mediated nutrient transport. Kniss et al. (1994) have shown that IGF-I stimulates transport of both glucose and amino acids in placental trophoblasts isolated from first trimester chorionic villi. Early studies using a choriocarcinoma cell line reported that IGFBP-1 inhibits IGF-I metabolic effects (Ritvos et al., 1988) but Yu et al. (1998) have demonstrated that the effect of IGFBP-1 is dependent upon its phosphorylation status. IGF-I-stimulated [ 3 H]α-amino isobutyric acid uptake by human trophoblast cells was inhibited by equimolar concentrations of phosphorylated IGFBP-1, whereas similar doses of non-phosphorylated IGFBP-1 enhanced IGF-mediated amino acid uptake. In these experiments, IGFBP-1 was incubated with the trophoblast cells for 24 h before addition of IGF, allowing for the IGFBP-1 interaction with cell surfaces which, as described above, may be important for the potentiating effects of IGFBP-1.
IGFBP-1 as a marker of fetal growth
If IGFBP-1 phosphorylation status were important for regulating IGF bioavailability and, therefore, for fetal growth, increased concentrations of the highly phosphorylated, so-called inhibitory, isoform might be expected in low birthweight infants. Iwashita et al. (1998) tested this hypothesis by analysing IGFBP-1 phosphoforms in fetal sera from pregnancies resulting in infants with different growth patterns. At term, the concentrations of non-phosphorylated IGFBP-1 were similar between appropriate for gestational age (AGA) and small for gestational age (SGA) fetuses; however, in comparison with AGA infants, phosphorylated isoforms of IGFBP-1 were increased in SGA fetuses, resulting in an increased ratio of phosphorylated to non-phosphorylated IGFBP-1. In twin pregnancies resulting in infants with discordant birthweights, a difference in the ratio of IGFBP-1 isoforms between the twins has been noted. Phosphorylated IGFBP-1 was increased in the cord serum from the smaller twin but there was no difference in the concentrations of non-phosphorylated IGFBP-1 (M. Westwood, unpublished) . This phenomenon is also apparent in maternal serum. In a study of type 1 diabetic pregnancy, phosphorylated IGFBP-1 concentration and, thus, the phosphorylated to nonphosphorylated IGFBP-1 ratio, was increased in those infants with the lowest birthweight . The capacity of the fetal-maternal unit to convert phosphorylated to nonphosphorylated IGFBP-1 may significantly affect fetal nutrition and, therefore, growth by increasing IGF bioavailability.
Although it has been suggested that IGFBP-1 concentrations in second trimester amniotic fluid might be a useful indicator of subsequent birthweight (Hakala-Ala-Pietila et al., 1993) , the ratio of phosphorylated to non-phosphorylated IGFBP-1 might be a better predictor of birthweight. The ratio can be determined readily by measuring IGFBP-1 in maternal serum from as early as week 18 of gestation and may identify pregnancies at risk of complications due to inadequate fetal growth.
Amniotic fluid IGFBP-1 may also be used in the diagnosis of premature rupture of membranes, a condition associated with increased maternal and fetal morbidity and mortality unless detected and treated quickly. IGFBP-1 in vaginal swab specimens has a positive predictive value of around 95% (Rutanen et al., 1993; Lockwood et al., 1994) .
Actions of IGFBP-1 in the mother
The non-phosphorylated and less phosphorylated IGFBP-1 present in the maternal circulation during pregnancy could be regarded as by-products of the events occurring at the decidualtrophoblast interface, but these isoforms may have a role in the mother too. The presence of non-phosphorylated IGFBP-1 may allow enhanced IGF activity to meet the increased demand on maternal metabolism and tissue growth during pregnancy, and may be part of a mechanism for increasing IGF bioavailability in pregnancy through IGFBP post-translational modification. IGFBP-2, -3 and -4 are all modified proteolytically in the maternal circulation, such that their affinity for IGF is reduced (Hossenlopp et al., 1990; Giudice et al., 1990; Davies et al., 1991) .
Mouse models
There have been no reports of mice carrying a null mutation for IGFBP-1, and IGFBP-1 transgenic mice have not proved to be particularly useful in determining the role of IGFBP-1 in pregnancy and fetal development since no consistent pattern has been discerned from the models reported. Various promoters have been used to control the expression of the transgene, hence some of the differences observed among the studies may be explained by inappropriate or absent expression in some tissues. In any case, data obtained using mouse models must be extrapolated with caution given the significant differences between mouse and human implantation and placental development. Furthermore, it is not known whether IGFBP-1 is phosphorylated in the mouse, although this may not be important since, in rats, phosphorylation status does not affect affinity for IGF (Peterkofsky et al., 1998) . Gay et al. (1997) reported impaired fertilization-implantation, reduced fetal survival and fetal growth retardation in transgenic animals, with high expression of human IGFBP-1 confined to the liver, indicating that circulating IGFBP-1 concentrations can affect reproduction. Several papers from Murphy and co-workers have also described reduced birthweight and litter size (Rajkumar et al., 1995; Huang et al., 1997) . However, expression of the transgene in either blastocyst or maternal tissues was thought not to affect implantation or fetal wastage significantly, since an equal number of wild-type and transgenic pups were born after blastocyst transfer to transgenic mothers. In contrast, Dai et al. (1994) observed no adverse effects on fetal growth and development.
New outlooks?
While changes in IGFBP-1 phosphorylation status during pregnancy may be an important mechanism for regulating IGF-I activity, this paradigm does not influence IGF-II bioavailability, since IGFBP-1 phosphorylation status does not affect its affinity for IGF-II (Westwood et al., 1997a) . However, decidualized endometrial cells produce a protease that can cleave IGFBP-1 into fragments of 14 and 17 kDa, but only when it is in the non-phosphorylated state. Western ligand and immunoblot analysis of the proteolytic fragments demonstrated that they have a markedly reduced affinity for IGF-I and IGF-II (Westwood et al., 1998) . Given the finding that the non-phosphorylated isoform represents up to 70% of IGFBP-1 at the fetal-maternal interface, IGFBP-1 proteolysis is likely to impact on the function of IGFBP-1 in this environment. The ability to modulate IGF-I and IGF-II bioavailability differentially by post-translational modification of IGFBP-1 may provide a sophisticated mechanism for controlling IGF-I (for example, metabolism) versus IGF-II (for example, migration) actions at the fetal-maternal interface (Fig. 2) . Future work will be required to identify the protease and its mode of action so that the role of IGFBP-1 during pregnancy can be better understood.
Conclusion
Insulin-like growth factors are key regulators of fetal and maternal tissue growth and development during pregnancy. Their actions on growth, metabolism and migration at the fetal-maternal interface are certainly influenced by IGFBP-1, and the paracrine-autocrine post-translational processing of this peptide is clearly important. However, despite the wealth of information of IGFBP-1 during pregnancy, its precise role remains to be elucidated.
